Articles related to MYELOMA

Whether in the outpatient or the inpatient setting, pharmacists can provide key support to patients and healthcare teams… performing due diligence to confirm the desired combination of drugs based on considerations such as patient age, CBC, comprehensive metabolic panel, and drug-drug interactions.

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

AL amyloidosis, a rare disease with an estimated global incidence of 10 cases per million population, can present with various symptoms depending on organ involvement, making early diagnosis challenging but crucial for effective treatment.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

High-risk iFISH markers, such as CKS1B, IGH-FGFR3, and del17p, significantly affect survival outcomes in newly diagnosed multiple myeloma patients, with marked differences observed between high-risk and standard-risk cohorts.